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Objective: To compare levels of persistency between cholinesterase inhibitors (ChEIs) among 
a Medicaid patient population of older adults.
Methods: Survival analysis was used to assess differences in discontinuation between ChEIs 
(donepezil versus rivastigmine and galantamine), and for difference in patient gender, age, 
race, and care setting.
Results: Rates of discontinuation increased from 42.7% (95% CI = 39.9–45.5) at 12 months 
to 84.8% (95% CI = 82.3–87.3) at 24 months. In multivariate models, no signiﬁ  cant differ-
ence in discontinuation existed prior to 365 days. However, patients dispensed donepezil were 
less likely to discontinue as compared with users of the other two ChEIs after the ﬁ  rst year 
(RR = 0.70; CI = 0.499–0.983; p   0.04). Patients of white race were less likely to discontinue 
(RR = 0.549; 95% CI = 0.43–0.82; p = 0.0015), while gender, care setting, and age were not 
associated with discontinuation.
Conclusions: One-year persistence rates were similar between different ChEIs. Among patients 
persisting with ChEI medication for at least 12 months, users of donepezil were slightly more 
likely to continue to persist at 24 months. Nearly half of patients failed to persist with ChEI 
therapy for at least 12 months. Our ﬁ  ndings underscore the limitations of the ChEI medica-
tions and the urgent need for effective and tolerable therapeutic options for patients having 
dementia.
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Background
Alzheimer’s Disease (AD) is an irreversible progressive disorder characterized by 
neuronal deterioration that results in loss of cognitive functions, such as memory, 
communication skills, judgment and reasoning (Lanctot et al 2003). It is a common 
(Fratiglioni 1993; Zuard 2001) and chronic dementia disorder among elderly people 
(Fratiglioni 1993), responsible for nearly 70% of all dementias (Zuard 2001). Approxi-
mately 4.5 million Americans suffer from AD in the US population, and this number 
is expected to increase almost 3-fold, to 13.2 million by 2050 (Hebert et al 2003). The 
incidence and prevalence of AD increases exponentially between the ages of 65 and 
85, approximately doubling every 5 years of age (Rocca et al 1991). The proportion 
of new onset cases who are 85 years of age or older is expected to increase from 42% 
in 1995 to 62% in 2050 (Hebert et al 2001). In 1995, 7.1% of all deaths in the US 
were attributable to AD, placing it on a par with cerebrovascular diseases as the third 
leading cause of death (Ewbank 1999). The 1991 estimate of total prevalent cost of 
the disease was $67.3 billion ($173,932 per case), with $20.6 billion in direct costs 
($47,581 per case) (Ernst and Hay 1994). It is a disease with signiﬁ  cant economic 
burden and a high societal impact, with the proportion of older adults increasing in 
the population (Fratiglioni 1993; Hebert et al 2003).Patient Preference and Adherence 2008:2 80
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The FDA approved 4 cholinesterase inhibitor drug 
therapies for AD: tacrine, donepezil, galantamine, and 
rivastigmine, collectively known as acetyl-cholinesterase 
inhibitors (ChEIs). By inhibiting the breakdown of the 
enzyme acetylcholine-esterase, these agents are hypothesized 
to prolong the action of acetylcholine at the postsynaptic 
receptor by preventing its hydrolysis. Cholinesterase inhibi-
tors are also prescribed for other conditions with cholinergic 
system dementia such as vascular dementia, Parkinson’s 
disease and multiple sclerosis dementia (Kloszewska 
2002). Though not curative, these medications can slow 
the progression of AD rather than reverse its progressive 
decline and have been shown to have a modest beneﬁ  cial 
impact on neuropsychiatric outcomes for AD patients (Trinh 
et al 2003). The major therapeutic effect on ChEI is to 
maintain a cognitive function at a stable level during a 6- to 
12-month period (Giacobini 2000a, b; Giacobini 2001a, b; 
Giacobini 2002). Additional drug effects are to slow down 
cognitive deterioration, improve behavioral problems, and 
increase ability to perform daily living activities (Jann 1998; 
Giacobini 2000a, b; Giacobini 2001a, b; Giacobini 2002) and 
improve the patient’s mood (Grutzendler and Morris 2001). 
Recent studies show that the cognitive stabilization effect 
may be prolonged up to 24 (Giacobini 2000a, b; Giacobini 
2001a; Giacobini 2002) to 36 months (Giacobini 2001b). The 
four therapies for AD differ by selectivity and speciﬁ  city for 
the brain tissue, as well as the ability to interact with other 
drugs, adverse events on the nervous system and gastroin-
testinal tract, and hepatotoxicity (Zuard 2001). Tacrine is 
no longer marketed in the US because of safety precautions 
(Clark and Karlawish 2003), and donepezil was the most 
frequently prescribed ChEI (Auriacombe et al 2002; Bullock 
and Connolly 2002) at the time of the study.
Persistence to these agents is expected to be suboptimal, 
as patients are often poorly adherent to chronic medications 
(Barat et al 2001; McDonald et al 2002). In a number 
of chronic illnesses, noncompliance to medications has 
been shown to have a signiﬁ  cant negative health impact 
(Luscher et al 1985; Col et al 1990; Psaty et al 1990; Chin 
and Goldman 1997; McDermott et al 1997; Bergen et al 
1998; Paterson et al 2000; Tsuyuki and Bungard 2001), 
and is estimated to cost the US $25 billion annually when 
indirect costs are included (Sullivan and Hazlet 1990). 
Older adults are especially prone to be non-adherent 
(Gray et al 2001) because of susceptibility to adverse 
events (Monane et al 1998; Golden et al 1999), deﬁ  cits 
in physical dexterity, cognitive skills and memory, and 
because of the large number of medications they are 
prescribed (Cramer 1998). Some researchers have found 
that older patients are generally more likely than younger 
patients to discontinue their medication (Applegate 2002; 
Benner et al 2002; Jackevicius et al 2002). Patients may 
discontinue ChEI drug therapy as a result of intolerable 
adverse events, rapid clinical deterioration, or failure to 
improve, stabilize, or reduce the rate of decline in AD (Fil-
lit and Cummings 2000). While persistence with speciﬁ  c 
ChEI medications has not been adequately examined by 
researchers, switching between different ChEIs has been 
frequently reported (Auriacombe et al 2002; Bullock and 
Connolly 2002; Emre 2002). There is limited information 
outside the clinical trial setting (Mauskopf et al 2005) and 
results of previous studies examining persistence to ChEIs 
have been inconsistent (Sicras and Rejas-Gutierrez 2004; 
Mauskopf et al 2005; Sicras-Mainar et al 2006) or have 
included only one type of ChEI (Roe et al 2002), thus 
preventing a comparison.
The objective of this research was to compare rates of 
persistence between donepezil and other types of ChEIs in 
usual care settings among a patient population of older adults 
enrolled in a state Medicaid program. Studies have reported 
donepezil to have better tolerability than the other ChEIs 
(Rogers et al 1998; Emre 2002; Inglis 2002; Wilkinson et al 
2002; Birks 2006). Thus, we assessed persistence with each 
ChEI medications separately, and overall.
Methods
Study population and design
We conducted a retrospective cohort study among patients 
enrolled in the Rhode Island Medicaid program between 
January 1, 2001 and December 31, 2003, and who received 
at least one dispensing for a ChEI medication. New users 
of ChEIs were identiﬁ  ed by selecting patients receiving 
an initial prescription for a ChEI medication between 
July 1, 2001 and December 31, 2003. Those included had 
no prior dispensing for a ChEI medication in the previous 
6 months, and an initial prescription prior to June 30, 2003, 
such that all patients had at least 6-months of follow-up 
time. Cases were excluded if they were less than 50 years 
of age. Information describing demographic and other 
patient characteristics was made available. Members with 
greater than a 6-month period (180 days) between reﬁ  lls, 
or between the last reﬁ  ll and the end of the study period 
were considered to have discontinued the drug. Switching 
to other types of cholinesterase inhibitors was assessed 
separately among those that continued their medication at 
6-months and at 1 year.Patient Preference and Adherence 2008:2 81
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Independent variables included class of ChEI dispensed 
(donepezil versus rivastigmine and galantamine), gender, age 
(age 50–69 years; or age 70 years or greater), race (white 
versus nonwhite), and care setting (long-term care setting 
versus community-dwelling). Categorizing age at 70 years 
was determined after performing an assessment of the para-
metric form for the age variable.
Descriptive statistics were used to determine the frequen-
cies of various patient characteristics. Survival analysis was 
used to assess differences in persistence among ChEIs prod-
uct dispensed, and by the patient characteristics identiﬁ  ed 
above. Kaplan-Meier (KM) curves were independently con-
structed for each of the predictor variables (class of ChEIs, 
gender, age, race, setting) and the log-rank statistic was used 
to evaluate group differences in persistence. Extended Cox 
proportional hazards models were used to estimate rate ratios 
(RR) and 95% conﬁ  dence intervals (CI) for the association 
between patient characteristics and ChEIs discontinuation. 
Statistical analyses were carried out using SAS statistical 
package version 8.01.
Results
A total of 1564 patients met the study’s inclusion criteria. 
Baseline characteristics of the population are presented in 
Table 1. The mean age of these patients was 83 years and 
76% were female. Most of the patient population were in 
long-term care (LTC) (86%) and 61% where of white race. 
Donepezil was the most widely dispensed ChEI accounting 
for 56.4% of the patients.
Table 2 presents the discontinuation rates at 12 
months and 24 months, overall and according to patient 
characteristics. Overall discontinuation increased with 
time from 42.7% (95% CI = 39.9–45.5) at 12 months, to 
84.8% (95% CI = 82.3–87.3) at 24 months. In univariate 
analyses, the initial type of dispensed ChEI medication was 
not associated with discontinuation (p = 0.22). During the 
ﬁ  rst 12 months, males were more likely to discontinue than 
females (p = 0.04) and whites were less likely to discontinue 
(p   0.0001) than non-white patients.
A small percentage of patients switched ChEI medication 
type during the study timeframe. Among patients who were 
started on donepezil and continued the medication for 6 and 
12 months, 96% remained on donepezil at 6 months and at 
12 months. At 6 months, 1% switched to rivastigmine and 
3% switched to galantamine and at 12 months 2% were 
receiving rivastigmine and 2% were receiving galantamine. 
Among patients who were started on rivastigmine 92% were 
still on rivastigmine at 6 months while 4.4% were switched 
to donepezil and 3.5% to galantamine. At 12 months, 89% 
were still on rivastigmine, 7.8% were receiving galantamine 
and 3.2% were receiving donepezil. Finally, among patients 
who were started on galantamine, 98% remained on galan-
tamine at 6 months, while 1.5% were switched to donepezil 
and 0.8 % to rivastigmine. At 12 months, 98.7% of these 
patients were receiving galantamine and 1.3% were receiving 
rivastigmine. The Medicaid plan had no inﬂ  uence on drug 
switches, as no restrictions on the use of any particular ChEI 
medication were in place during the study timeframe.
In multivariate models, persistence rates did not differ 
among ChEI medication use as assessed during the ﬁ  rst 
12 months of therapy (RR = 1.002; CI = 0.807–1.243; 
p = 0.9879). Among those persisting for at least 12 months, 
users of donepezil were less likely to discontinue during 
subsequent months as compared with users of the other two 
ChEIs (RR = 0.70; CI = 0.499–0.983; p   0.0397). Overall, 
patients of white race showed better persistence than of non-
white race (RR = 0.549; 95% CI = 0.43–0.82; p = 0.0015). 
This, however, was based on 66% of the population since 
34% had missing values for race. Gender, care setting, and 
age were not associated with differences in discontinuation. 
These results are presented in Table 3. Figure 1 shows the 
survival curves for those dispensed donepezil vs other ChEI 
medications.
Discussion
Our ﬁ  ndings suggest that discontinuation rates for ChEIs 
are high, as previously reported (Roe et al 2002; Sicras 
and Rejas-Gutierrez 2004; Mauskopf et al 2005; Sicras-
Mainar et al 2006), and indicate slightly better persistence 
Table 1 Characteristics of new users of cholinesterase inhibitor 
(ChEI) medications (n = 1564)
Characteristic   n  (%)
Gender Females  1190  (76.1%)
 Males  374  (23.9%)
Age (years)  Mean  83.1
  SD       9.1
   70 1435  (91.8%)
 50–69  129  (8.2%)
Race White  956  (61.1%)
 None-white  75  (4.8%)
 Missing  533  (34.1%)
Initial type of ChEI   Donepezil  882 (56.4%)
medication dispensed  Rivastigmine  317 (20.3%)
 Galantamine  365  (23.3%)
Setting Long-term  care  1340  (85.7%)
 Community  224  (14.3%)
Abbreviation: SD, standard deviation.Patient Preference and Adherence 2008:2 82
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with donepezil than other ChEIs beyond 1 year of therapy, 
adjusting for gender, age, race, and living arrangements 
(adjusted RR = 0.70; CI = 0.499–0.983; p   0.0397). 
Similar rates of persistence for all ChEI medications for the 
ﬁ  rst 12 months of use were observed (adjusted RR = 1.002; 
CI = 0.807–1.243; p = 0.9879).
Patients of white race were shown to have better persistence 
than nonwhites (41% vs 69%), although this ﬁ  nding was based 
on an analysis of only 66% of the study population, as 34% of 
individuals had no information describing race in the available 
data sources. Despite the high rate of missing values for this 
variable, we believed that it was important to include this 
covariate in our analysis given the magnitude of difference 
in the percentages persisting, and because race has also been 
reported to be among factors associated with noncompliance 
(Balkrishnan 1998). The smaller percentage of nonwhite cases 
overall merits further analysis, as it is possible that nonwhite 
patients were less frequently prescribed ChEI medications. 
In the multivariate analysis, we did not ﬁ  nd persistence rates 
to differ signiﬁ  cantly when assessing by patient age, gender, 
or by living arrangement. Other researchers evaluating these 
factors have described inconsistent ﬁ  ndings (Coons et al 1994; 
Balkrishnan 1998).
Table 2 Discontinuation rates of cholinesterase inhibitors medications at 12 and 24 months (n = 1564)
Variable   Discontinued by      Discontinued by    Log rank
    12 months      24 months    probability
   n  %  CI  n  %  CI
Total population  513/1199  42.7%  (39.9%–45.5%)  692/816  84.8%  (82.3%–87.3%)
Initial type of             0.2218 
medication dispensed
 Donepezil  279/673  41.4%  (37.7%–45.1%)  373/442  84.4%  (81.0%–87.8%)
 Rivastigmine  115/250  46.0%  (39.8%–52.2%)  158/184  85.9%  (80.9%–90.9%)
 Galantamine  119/277  43.0%  (37.1%–48.8%)  162/190  85.3%  (80.3%–90.3%)
Gender           0.0405*
 Female  373/919  40.6%  (37.4%–43.7%)  515/615  83.7%  (80.8%–86.6%)
 Male  140/282  49.6%  (43.8%–55.4%)  177/201  88.1%  (83.6%–92.6%)
Age           0.1475
 50–69  459/1102  41.7%  (38.7%–44.5%)  629/740  85.0%  (82.4%–87.5%)
   70 54/100  54.0%  (44.2%–63.8%)  63/75  84.0%  (75.7%–92.3%)
Race            0.0001*
 White  303/742  40.8%  (37.3%–44.3%)  417/496  84.1%  (80.9%–87.3%)
 Non-white  42/61  68.9%  (57.3%–80.5%)  47/48  97.9%  (93.8%–101.9%)
Setting           0.3202
 Long-term  care  430/1037  41.5%  (38.5%–44.5%)  594/707  84.0%  (81.3%–86.7%)
 Community  83/165  50.3%  (42.7%–57.9%)  98/109  89.9%  (84.2%–95.6%)
*Signiﬁ  cant result p   0.05.
Abbreviation: CI, conﬁ  dence interval.
Table 3 Adjusted associations between patient characteristics and 
discontinuation of cholinesterase inhibitors (ChEI) medications 
(n = 1564)
Variable  Adjusted rate ratio  95% CI
Initial type of ChEI 
medication dispensed, 
persistence up to 365 days
  Galantamine or rivastigmine  1.0 (reference)
 Donepezil  1.002  0.807–1.243
Initial type of ChEI 
medication dispensed, 
persistence beyond 365 days
  Galantamine or rivastigmine  1.0 (reference)
 Donepezil  0.700*  0.499–0.983
Gender
 Female  1.0  (reference)
 Male  1.082  0.877–1.335
Age
  50–69 years  1.0 (reference)
   70 years  0.898  0.672–1.202
Race
 Non-white  1.0  (reference)
 White  0.594*  0.430–0.820
Setting
 Community  1.0  (reference)
  Long term care  0.873  0.672–1.135
*Signiﬁ  cant result.
Abbreviation: CI, conﬁ  dence interval.Patient Preference and Adherence 2008:2 83
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Two studies carried out in primary care health centers in 
Spain (Sicras and Rejas-Gutierrez 2004; Sicras-Mainar et al 
2006) also demonstrated better persistence of donepezil than 
rivastigmine and galantamine. Mauskopf et al (2005) found 
similar rates of persistence between rivastgmine and donepe-
zil in a retrospective community-based study. This research, 
however, looked at 6 months of medication persistence and 
did not evaluate persistence rates after 1 year. Thus, our 
results are consistent since we found no signiﬁ  cant differ-
ence in persistence prior to 1 year of therapy. Furthermore, 
Mauskopf et al (2005) recognized that the limited sample 
size of rivastgmine patients might have limited the authors’ 
ability to detect differences in persistence.
Leading reasons for discontinuation of ChEI therapy 
include patient or physician-perceived ineffectiveness, intol-
erance of side effects, or an inconvenient dosing schedule 
(Mauskopf et al 2005). Reported side effects include nausea, 
vomiting, and diarrhea (Rogers and Friedhoff 1996; Rogers 
et al 1998; Emre 2002; Mauskopf et al 2005). Donepezil has 
been reported to have better tolerability and a milder side effect 
proﬁ  le than other ChEIs (Rogers et al 1998; Emre 2002; Inglis 
2002; Wilkinson et al 2002) which might explain the observed 
difference in persistency rates beyond 1 year. This, nonetheless, 
does not explain why similar persistency rates were observed 
prior to 1 year, since side effects are expected to start before 1 
year. Additionally, based on comparison of persistence rates, 
our results do not support reports that rivastigmine provides 
a higher magnitude of beneﬁ  ts than donepezil (Rogers et al 
1998; Emre 2002; Inglis 2002; Wilkinson et al 2002).
The cost-effectiveness of ChEI therapy has been ques-
tioned, particularly given the high direct cost for these 
medications (Clegg et al 2001, 2002; Fillit and Hill 2004; 
Curtiss 2005; Loveman et al 2006). Outcome evaluations 
should also consider the quality of life of the patient and of 
care givers, and the importance of developing a quality of 
life instrument for both (Loveman et al 2006). It is difﬁ  cult to 
quantify beneﬁ  ts as reported in the literature since improve-
ments in tests such as ADAS-cog (Alzheimer’s Disease 
Assessment Scale cognitive subscale) may not be reﬂ  ected 
in changes of daily life (Clegg et al 2001).
Because there is currently no cure for AD, one cannot 
expect the initial cognitive improvement observed in the ﬁ  rst 
few months of therapy to be sustained indeﬁ  nitely. However, 
one should expect that some patients who are treated early 
and persistently with AD medications will show less evidence 
of behavioral and cognitive deterioration over a period of 
time than one would expect in the absence of pharmaco-
therapy, and less decline over the long term (Geldmacher et al 
2006). By reducing cognitive and functional declines over 
time, long-term therapy may enable patients to stay at home 
Figure 1 Survival curves of new users of donepezil versus other cholinesterase inhibitor medications (n = 1564).
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longer and decrease the burden faced by patients, caregivers, 
and society (Geldmacher 2003). Geldmacher et al (2003) 
reported that taking donepezil for 9–12 months delays nurs-
ing home placement. Hill et al ( 2002) demonstrated lower 
costs for 204 AD patients in a large Medicare managed care 
plan on donepezil compared with 204 patients not receiving 
therapy with matched characteristics, where annual costs of 
prescriptions and medical services were $3,891 lower for the 
study group. Longer term therapy ( 270 days) also achieved 
lower costs compared to shorter term therapy. In our study 
population, 686 (57.3%) patients remained on therapy for 12 
months, a ﬁ  gure that may represent a cost-savings consider-
ing the potential outcomes described above.
Several limitations to this study can be described. Clinical 
data regarding diagnosis, doses used, and exact reason for dis-
continuation were lacking. Prescription dispensing data were 
used to evaluate persistence, and ﬁ  lling the prescription does 
not ensure that the drug was actually consumed. Nonetheless, 
reﬁ  ll data are considered more objective than self-report which 
can overestimate compliance (Choo et al 1999), and is a useful 
tool to assess the drug use in population-based studies (Steiner 
and Prochazka 1997). We could not account for use of samples 
or hospitalizations during a follow-up period. However, we 
believe that our criterion of 6 months without a prescription 
being dispensed to be classiﬁ  ed as nonpersistent mitigates the 
potential inﬂ  uence of these factors because it would be difﬁ  cult 
to obtain drug samples that cover such a long period of time 
and it is a long period for a continuous hospitalization. Severity 
of AD was not assessed, but including newly treated patients 
in the study addresses this concern to some degree, and these 
medications were approved for only use in mild to moderate 
disease as of the time of the study. We were unable to control 
for potential confounders pertaining to patient co-morbidi-
ties, and 34% of the population had missing values for race. 
Additionally, as all the patients were enrolled in a Medicaid 
program, they are expected to be of lower incomes and to have 
no co-payments for medications. This, however, might limit 
generalizability of the results to other populations.
While the improvements gained with the use of ChEI 
medications may be small or modest, sustained beneﬁ  ts 
of therapy can be realized only by patients who persist with 
therapy. Yet our results indicate that persistence rates with 
these medications are quite low. Persistence rates were higher 
for donepezil users compared with those who received other 
ChEI medication beyond 12 months, yet given the marginal 
difference and the limitations of our data source, we are 
unable to conclude that this difference suggests superiority 
of donepezil.
Conclusions
We found similar persistence rates for each of the three avail-
able ChEI medications, with a 42% rate of persistence at 12 
months, and those dispensed donepezil were slightly more 
likely to persist at 24 months. While we were not able to 
ascertain if discontinuation was due to lack of efﬁ  cacy or lack 
of tolerability, our analyses revealed that nearly half of patients 
failed to persist with ChEI therapy for at least 12 months. Our 
ﬁ  ndings underscore the limitations of the ChEI medications and 
the urgent need for effective and tolerable therapeutic options 
for patients having dementia. From a drug policy perceptive, the 
consideration of the utility of ChEI medications should include 
both results from clinical trials and insights from observational 
studies such as ours, which reveal that for many patients ChEI 
medications cannot be relied upon to provide longer-term 
beneﬁ  t in managing dementia. Reports describing measures of 
therapy persistence can be important to caregivers and patients 
in forming expectations for pharmacotherapy.
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